Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))

on behalf of the SHP609-302 study group

Research output: Contribution to journalComment/debatepeer-review

Abstract

The following text in the abstract incorrectly states the percentage of patients with at least one adverse event related to idursulfase-IT. ‘Overall, 25.0% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The text should read as follows. ‘Overall, 78.6% of patients had at least one adverse event (AE) related to idursulfase-IT;’ The data are otherwise reported correctly in the article text and in Table 2. The authors would like to apologize for any inconvenience caused.

Original languageEnglish (US)
Article number107646
JournalMolecular Genetics and Metabolism
Volume140
Issue number3
DOIs
StatePublished - Nov 2023

ASJC Scopus subject areas

  • Genetics
  • Endocrinology
  • Molecular Biology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Corrigendum to “Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II” (Molecular Genetics and Metabolism (2022) 137(1–2) (92–103), (S1096719222003833), (10.1016/j.ymgme.2022.07.016))'. Together they form a unique fingerprint.

Cite this